Wagering on Unfinished Experiments-Prediction Markets and Clinical Trial Integrity.

A prediction market platform’s plan to host bets on clinical trial outcomes and US Food and Drug Administration regulatory reviews raises concerns about clinical trial integrity and public interest.

• Why it matters: If such wagering affects recruitment, retention, measurement, or evidence generation, it could distort how trials run and how regulatory decisions are supported.
• What they did: The Viewpoint analyzes the potential downstream effects of allowing prediction markets to cover clinical trials and FDA regulatory reviews, and calls for policy action.
• The result: It argues that policy is needed to prevent prediction markets from undermining the public interest while they operate in this clinical and regulatory context.

AI summary of the abstract · may contain errors · not medical advice · read the paper.